A National Cancer Institute of Canada Clinical Trials Group Study – IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer
Jean A. Maroun(American Society of Clinical Oncology), G. Chiritescu(Ottawa Hospital), Lesley Seymour(Queen's University), Anne Malpage, D Lister(Ottawa Hospital), Derek J. Jonker(University of Ottawa), C. Cripps(Canadian Partnership Against Cancer), Mark Vincent, Rakesh Goel(Ottawa Hospital), Walter Kocha(Occupational Cancer Research Centre), B. Fisher(Ontario Institute for Cancer Research)
Cited by 9
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k